3 Stocks Advancing The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 27 points (0.2%) at 17,793 as of Tuesday, June 9, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,256 issues advancing vs. 1,750 declining with 142 unchanged.

The Drugs industry currently sits down 1.3% versus the S&P 500, which is up 0.1%. A company within the industry that increased today was Eli Lilly and ( LLY), up 0.8%. On the negative front, top decliners within the industry include Dyax ( DYAX), down 6.2%, Neurocrine Biosciences ( NBIX), down 5.8%, Opko Health ( OPK), down 4.5%, Alkermes ( ALKS), down 3.6% and Alnylam Pharmaceuticals ( ALNY), down 3.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Grifols ( GRFS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Grifols is up $0.59 (1.9%) to $31.09 on light volume. Thus far, 173,354 shares of Grifols exchanged hands as compared to its average daily volume of 493,300 shares. The stock has ranged in price between $30.56-$31.10 after having opened the day at $30.83 as compared to the previous trading day's close of $30.50.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. Grifols has a market cap of $10.7 billion and is part of the health care sector. Shares are down 8.2% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Grifols a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Grifols Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Illumina ( ILMN) is up $3.49 (1.7%) to $214.15 on heavy volume. Thus far, 957,162 shares of Illumina exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $209.00-$214.80 after having opened the day at $210.00 as compared to the previous trading day's close of $210.66.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $30.3 billion and is part of the health care sector. Shares are up 13.9% year-to-date as of the close of trading on Monday. Currently there are 12 analysts who rate Illumina a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Illumina Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Gilead ( GILD) is up $1.22 (1.1%) to $114.92 on average volume. Thus far, 5.0 million shares of Gilead exchanged hands as compared to its average daily volume of 11.1 million shares. The stock has ranged in price between $113.15-$115.23 after having opened the day at $113.22 as compared to the previous trading day's close of $113.70.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $167.5 billion and is part of the health care sector. Shares are up 20.9% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Gilead a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists